Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma

Expert Review of Anticancer Therapy
Pol Specenier, Jan Vermorken

Abstract

The majority of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M HNSCC) is rapidly evolving. Areas covered: This article will comprehensively review the current systemic treatment of R/M HNSCC. Expert commentary: For the time being, the EXTREME regimen (cetuximab in combination with platinum and 5-fluorouracil) still remains standard of care in previously untreated R/M HNSCC patients who are candidates for combination chemotherapy. Single agents with well documented activity in HNSCC include methotrexate, cisplatin, 5-FU, docetaxel, and paclitaxel. The anti-PD-1 monoclonal antibody nivolumab can be considered the current standard of care in patients with R/M HNSCC progressing after platinum-based therapy based on the results of CheckMate 141 showing a survival benefit over standard of care drugs, such as single agent weekly cetuximab, methotrexate, or docetaxel. Multiple randomized phase III trials comparing anti-PD(L)-antibodies either as single agent or in combination with chemotherapy or an anti-CTLA-4 with the EXTREME as fist line treatment are ongoing or planned. The outcome of these trials might change the current treatment pa...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C JacobsL Schacter
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A PaccagnellaV C Sileni
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Denis SoulieresLillian L Siu
Sep 3, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E GuardiolaX Pivot
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael K GibsonUNKNOWN Eastern Cooperative Oncology Group
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstMerrill S Kies
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara BurtnessUNKNOWN Eastern Cooperative Oncology Group
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ezra E W CohenEverett E Vokes
Jun 9, 2006·Cancer Biology & Therapy·Athanassios ArgirisEverett Vokes
Jun 7, 2007·American Journal of Clinical Oncology·Jean-Luc LaboureyNicole Tubiana-Mathieu
Feb 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B A BurtnessUNKNOWN Eastern Cooperative Oncology Group
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Simon W StewartEverett E Vokes
Aug 4, 2009·Investigational New Drugs·Nicholas W ChoongEzra E W Cohen
Aug 6, 2009·Cancer Chemotherapy and Pharmacology·George FountzilasMarios Marselos
Oct 24, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C H ChungB A Murphy
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pascal H MachielsJoel Guigay
Mar 26, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R MesíaJ B Vermorken
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen K WilliamsonSusan G Urba
Aug 11, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y-W WonK Park
Oct 13, 2010·American Journal of Clinical Oncology·Pol SpecenierJan B Vermorken
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B Vermorken, P Specenier
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Athanassios ArgirisMarjorie Romkes

❮ Previous
Next ❯

Citations

Nov 18, 2018·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·Fei LiuQiang Sun
Jul 1, 2020·Laryngoscope Investigative Otolaryngology·Madeline P Pyle, Michael Hoa
Oct 6, 2020·Expert Opinion on Drug Metabolism & Toxicology·Maud MaillardEtienne Chatelut
Apr 14, 2019·Trends in Pharmacological Sciences·Hélène LajousEmmanuel Garcion
Aug 8, 2021·Journal of Experimental & Clinical Cancer Research : CR·Daniel StrüderClaudia Maletzki
Nov 26, 2021·Thoracic Cancer·Xi ChenYingying Jiang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.